CDT Equity Inc Dossier
Qualitative Analysis
Business overview
CDT Equity Inc. (formerly known as Conduit Pharmaceuticals Inc.) is a clinical-stage, data-driven specialty biopharmaceutical development company. The company focuses on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, solid-form chemistry, and strategic partnerships. Rather than pursuing traditional capital-intensive drug development, CDT Equity utilizes a capital-efficient model centered on out-licensing and intellectual property creation. Its pipeline includes clinical assets targeting autoimmune disorders, idiopathic male infertility, oncology, dermatology, and animal health. Key pipeline candidates include AZD1656, a glucokinase activator in Phase II trials for autoimmune disorders, and AZD5904, which has completed Phase I trials for idiopathic male infertility. In addition, CDT Equity holds a strategic equity stake in Sarborg Limited, an agentic AI signature intelligence business.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic pivot positioning CDT as a capital-efficient, out-licensing business model. The strategy focuses on identifying clinically validated or underutilized assets, enhancing them through proprietary solid-form and cocrystallization technologies to extend patent life, and leveraging AI-driven analysis to identify high-probability indications.
Expected impact: Enables CDT to generate curated, partner-ready data packages for out-licensing, minimizing exposure to late-stage clinical development costs and risks while creating multiple revenue avenues (upfronts, milestones, royalties).
Filing of two new patent applications surrounding tapinarof (currently approved for psoriasis and atopic dermatitis). The first covers a combination therapy pairing tapinarof with clinically proven drugs, and the second relates to novel cocrystal forms of tapinarof with these agents.
Expected impact: Aims to underpin a second-generation tapinarof product with enhanced formulation properties and efficacy, extending the asset's lifecycle and broadening its clinical scope to underserved dermatological conditions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a 20% strategic minority equity stake in Sarborg Limited, an agentic signature intelligence business, to integrate advanced AI-driven analysis across CDT's asset portfolio.
Financial impact: Consideration included 598,006 CDT common shares, pre-funded warrants for up to 109,978,918 shares, and $8 million in deferred cash. As of June 18, 2026, following a third-party funding round, the implied value of CDT's 1,020-share holding in Sarborg jumped to $127.5 million.
Strategic Partnerships
Provides the foundational clinical assets for CDT's pipeline, including AZD1656, AZD5658, and AZD5904, which benefit from extensive established clinical safety profiles.
Terms: Enables CDT to enhance and reposition these assets for subsequent out-licensing to late-stage development partners.
Formulation development CDMO partnership to develop new solid oral-dosage form products, supporting CDT's proprietary solid-form and cocrystal innovation programs.
Terms: Fee-for-service formulation development.